Newdick C
Department of Law, University, Reading, UK.
Blood Coagul Fibrinolysis. 1994 Dec;5 Suppl 4:S37-8. doi: 10.1097/00001721-199412004-00011.
There is no legislation specifically designed to compensate haemophilia patients who have been damaged by defective blood products. But there is a general regime, created as a result of the thalidomide tragedy, which deals with defective 'products'. It was introduced at the European level by the European Directive on Product Liability in 1985 and has been given effect in England by the Consumer Protection Act 1987. The rights of haemophilia patients who are injured by defective blood products depends on this Directive.
目前尚无专门立法用于补偿因有缺陷血液制品而受到损害的血友病患者。但因沙利度胺悲剧而产生了一套针对有缺陷“产品”的通用制度。该制度于1985年由欧洲《产品责任指令》在欧洲层面引入，并通过1987年《消费者保护法》在英国生效。因有缺陷血液制品而受伤的血友病患者的权利取决于该指令。
